Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000358229

Medchemexpress LLC Ruxolitinib (S enantiomer) | 941685-37-6 | 99.6% | C17H18N6 | 100 MG
SDP

Catalog No. 5000358229
Encompass_Preferred

Ruxolitinib (S enantiomer) is the S-enantiomer of Ruxolitinib (HY-50856). It is an orally active, potent JAK inhibitor, intended for research use only.

  • Orally active
  • Potent JAK inhibitor
  • Suppresses IFNβ-induced expression of ISG, IFIT, and IFITM in human small airway epithelial cells (SAECs) at 10 μM for 12 hours
  • Reduces haematopoietic cell expansion in myeloproliferative neoplasms (MPN) in animal models (30 mg/kg, oral gavage, twice per day for 8 weeks)

Catalog No. 50-003-58229 Supplier Medchemexpress LLC Supplier No. HY50856A100MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Ruxolitinib (S enantiomer) is the S-enantiomer of Ruxolitinib (HY-50856). It is an orally active, potent JAK inhibitor, intended for research use only.

  • Orally active
  • Potent JAK inhibitor
  • Suppresses IFNβ-induced expression of ISG, IFIT, and IFITM in human small airway epithelial cells (SAECs) at 10 μM for 12 hours
  • Reduces haematopoietic cell expansion in myeloproliferative neoplasms (MPN) in animal models (30 mg/kg, oral gavage, twice per day for 8 weeks)

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.